FDA drug center director Janet Woodcock has been pegged as a potential front-runner for the full-time commissioner position ever since she was named acting agency chief by President Joe Biden. But Marc Scheineson, partner at Alston & Bird and a former FDA associate commissioner, says that by putting her in the acting role, it’s unlikely the Biden administration will nominate her for the permanent role, as agency heads typically come from outside the agency’s career force, even though she might...